Recessive Ttn Truncating Mutations Define Novel Forms of Core Myopathy with Heart Disease
![](/xmlui/themes/Mirage2//images/mime2.png)
Date
2014Author
Chauveau, Claire
Bonnemann, Carsten G.
Julien, Cedric
Kho, Ay Lin
Marks, Harold
Talim, Beril
Maury, Philippe
Arne-Bes, Marie Christine
Uro-Coste, Emmanuelle
Alexandrovich, Alexander
Vihola, Anna
Schafer, Sebastian
Kaufmann, Beth
Medne, Livija
Huebner, Norbert
Foley, A. Reghan
Santi, Mariarita
Udd, Bjarne
Topaloglu, Haluk
Moore, Steven A.
Gotthardt, Michael
Samuels, Mark E.
Gautel, Mathias
Ferreiro, Ana
xmlui.mirage2.itemSummaryView.MetaData
Show full item recordAbstract
Core myopathies (CM), the main non-dystrophic myopathies in childhood, remain genetically unexplained in many cases. Heart disease is not considered part of the typical CM spectrum. No congenital heart defect has been reported, and childhood-onset cardiomyopathy has been documented in only two CM families with homozygous mutations of the TTN gene. TTN encodes titin, a giant protein of striated muscles. Recently, heterozygous TTN truncating mutations have also been reported as a major cause of dominant dilated cardiomyopathy. However, relatively few TTN mutations and phenotypes are known, and titin pathophysiological role in cardiac and skeletal muscle conditions is incompletely understood. We analyzed a series of 23 families with congenital CM and primary heart disease using TTN M-line-targeted sequencing followed in selected patients by whole-exome sequencing and functional studies. We identified seven novel homozygous or compound heterozygous TTN mutations (five in the M-line, five truncating) in 17 patients. Heterozygous parents were healthy. Phenotype analysis identified four novel titinopathies, including cardiac septal defects, left ventricular non-compaction, EmeryDreifuss muscular dystrophy or arthrogryposis. Additionally, in vitro studies documented the first-reported absence of a functional titin kinase domain in humans, leading to a severe antenatal phenotype. We establish that CM are associated with a large range of heart conditions of which TTN mutations are a major cause, thereby expanding the TTN mutational and phenotypic spectrum. Additionally, our results suggest titin kinase implication in cardiac morphogenesis and demonstrate that heterozygous TTN truncating mutations may not manifest unless associated with a second mutation, reassessing the paradigm of their dominant expression.